Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

COULD VENTURE BE A FASTER ROUTE TO CURING CANCER?

JOIN US TO DISCOVER HOLY-GRAIL APPROACHES AND LAUNCH YOUR OWN COMPANY.
Cancer Research UK has partnered with Deep Science Ventures to create an opportunity for early career stage researchers to build ventures that target the complexity of biology. We are currently recruiting people with specialist domain knowledge who want to co-found biotech companies. No prior IP or “idea” required.
Cancer Research UK has partnered with Deep Science Ventures to create an opportunity for early career stage researchers to build ventures that target the complexity of biology. We are currently recruiting people with specialist domain knowledge who want to co-found biotech companies. No prior IP or “idea” required.

Interviews ongoing

Interviews ongoing

About the partnership

This partnership brings together the world’s largest independent funder of cancer research with the unique venture design process of Deep Science Ventures to create a programme that is exhaustive in the search for the best approach from both technical and commercial perspectives, and positioned for new venture growth from day one. Our aim is to identify and bring together entrepreneurial scientists, academic advisors and investors to design and build new companies in oncology.

 

Who’s it for?

The programme is open to early career researchers with interest in science entrepreneurship. We are not looking for ideas, but for highly driven people with expertise in oncology and an overwhelming desire to change the way things are done.

About the partnership

This partnership brings together the world’s largest independent funder of cancer research with the unique venture design process of Deep Science Ventures to create a programme that is exhaustive in the search for the best approach from both technical and commercial perspectives, and positioned for new venture growth from day one. Our aim is to identify and bring together entrepreneurial scientists, academic advisors and investors to design and build new companies in oncology.

 

Who’s it for?

The programme is open to early career researchers with interest in science entrepreneurship. We are not looking for ideas, but for highly driven people with expertise in oncology and an overwhelming desire to change the way things are done.

How does it work if I don’t have an idea?

We are not looking for IP or any sort of business plan. Simply review which of the three opportunity areas below you are most excited about and for which you have relevant experience. Click on each area to learn more.

How does it work if I don’t have an idea?

We are not looking for IP or any sort of business plan. Simply review which of the three opportunity areas below you are most excited about and for which you have relevant experience. Click on each area to learn more.

Application process

We review applications within 5 working days from when they come in and will get back in touch to learn more about you if necessary. We normally make a decision within 2 weeks of application submission.

Application process

We review applications within 5 working days from when they come in and will get back in touch to learn more about you if necessary. We normally make a decision within 2 weeks of application submission.

Why join?

Boost your career

It can be challenging for an early career researcher to even consider attempting venture, tending to assume that if things go wrong it will look bad and set back an academic career. In reality, it’s quite the opposite. It’s common for our founders to actually publish more papers and with higher level co-authors in addition to filing more patents as a founder than they did in academia. Learn more in our blog post on Nature Jobs.

Meet like-minded people

The “T-shape” people – those who are creative, systematic, deep and broad across technical domains, and make great founders – are surprisingly rare and don’t look like what many people imagine as an ‘entrepreneur’. At DSV we’ve spent over 10 years learning to find these characters and match with complimentary skill-sets. If you like the sound of taking a moment to join the dots across the landscape, discussing ideas with a diverse range of people and then moving really fast to achieve set outcomes, then you’re a fit!

A proven framework & training

After spending 10 years in university tech transfer, venture studios, and corporate innovation arms, we’ve developed and proved a better framework for venture creation. In the past two years we’ve launched 20 companies, consistently identifying opportunities that others are missing.

Funding

Each company will be created with £50,000 to cover initial proof of principle work. DSV may follow on up to £500,000 and Cancer Research UK is launching several seed, grant and later stage funding initiatives that may be relevant on a case by case basis.

Ownership

Founders will own 90% of the company at formation including formation capital.

Why join?

Boost your career

It can be challenging for an early career researcher to even consider attempting venture, tending to assume that if things go wrong it will look bad and set back an academic career. In reality, it’s quite the opposite. It’s common for our founders to actually publish more papers and with higher level co-authors in addition to filing more patents as a founder than they did in academia. Learn more in our blog post on Nature Jobs.

Meet like-minded people

The “T-shape” people – those who are creative, systematic, deep and broad across technical domains, and make great founders – are surprisingly rare and don’t look like what many people imagine as an ‘entrepreneur’. At DSV we’ve spent over 10 years learning to find these characters and match with complimentary skill-sets. If you like the sound of taking a moment to join the dots across the landscape, discussing ideas with a diverse range of people and then moving really fast to achieve set outcomes, then you’re a fit!

A proven framework & training

After spending 10 years in university tech transfer, venture studios, and corporate innovation arms, we’ve developed and proved a better framework for venture creation. In the past two years we’ve launched 20 companies, consistently identifying opportunities that others are missing.

Funding

Each company will be created with £50,000 to cover initial proof of principle work. DSV may follow on up to £500,000 and Cancer Research UK is launching several seed, grant and later stage funding initiatives that may be relevant on a case by case basis.

Ownership

Founders will own 90% of the company at formation including formation capital.

Case studies

We know that we can’t resolve the key challenges of our time simply by unlocking structural efficiencies. However, over the last 2 years we have tackled over 15 major challenges and developed viable solutions that have moved some fields forward by as much as 10 years. We aim to do the same in oncology.

Case studies

We know that we can’t resolve the key challenges of our time simply by unlocking structural efficiencies. However, over the last 2 years we have tackled over 15 major challenges and developed viable solutions that have moved some fields forward by as much as 10 years. We aim to do the same in oncology.

Dr Alexandra Sakatos, PhD in Microbiology from Harvard University

Why are microbiome therapeutics failing?

We know that the gut microbiome drives many diseases, yet trials fail because they only consider part of the ecosystem: the bacterial component of microbiome is less than half of the picture. Working with the University of Washington, Ancilia has built the first comprehensive platform that maps the other half of the ecosystem - the virome - and are equipping bacteria with genetic immunity to disease-causing phage.

Eilish Middlehurst, NHS Clinical Entrepreneur

How do we improve existing cancer treatment outcomes?

All cancer treatments create resistance but if sequenced correctly up to 30% of lives could be saved using existing therapeutics. Working with Mayo Clinic, ConcR designed evolutionary algorithms that correctly predict the most effective combination with 90% accuracy.

Dr Alexandra Sakatos, PhD in Microbiology from Harvard University

Why are microbiome therapeutics failing?

We know that the gut microbiome drives many diseases, yet trials fail because they only consider part of the ecosystem: the bacterial component of microbiome is less than half of the picture. Working with the University of Washington, Ancilia has built the first comprehensive platform that maps the other half of the ecosystem - the virome - and are equipping bacteria with genetic immunity to disease-causing phage.

Eilish Middlehurst, NHS Clinical Entrepreneur

How do we improve existing cancer treatment outcomes?

All cancer treatments create resistance but if sequenced correctly up to 30% of lives could be saved using existing therapeutics. Working with Mayo Clinic, ConcR designed evolutionary algorithms that correctly predict the most effective combination with 90% accuracy.

FAQ

Can I speak to someone?

Yes, email us at cruk@dsv.io

Does it matter where I’m based?

Remote is fine as long as you’re in a relevant cluster for your work (this includes outside the UK).

‘I have an idea…’

That’s great, the kind of people we’re looking for have lots of ideas, but you’ll need to be open to systematically breaking down a problem and not stuck on one idea, if that’s the case then we’d love to hear from you.

Are there labs?

We don’t have dedicated labs, as the kind of experiments we wish to do usually require specific kit and expertise. We do have a range of great relationships with existing labs and have supported many teams to work out a way forward with academic advisors or CROs for the initial proof of principle prior to seed investment.

What if it doesn’t work / I can’t find the solution?

We haven’t had a single case yet where we haven’t found a groundbreaking solution, but as a Founder if this happens you’ll likely join one of the labs you’ve been working with to prototype ideas, join a startup that you meet along the way, or work with one of the industry partners you’ve met. Overall, for a minor gap in blue-sky research you gain a world of connections and a wealth of impact experience that most labs are crying out for.

Who owns the IP?

The IP developed as part of the project will temporarily be held by DSV and assigned to the new company on formation. Any required background IP owned by research councils / charities / universities may be licensed via normal negotiation with those institutions. Where foreground IP is developed with a university, terms will be agreed as part of the research contact with that university.

Are there mentors?

Yes, both DSV and Cancer Research UK have a wide network of exited founders and investors. We think it’s pretty crass to have a big wall of faces, we’ll just connect you to the right people at the right time.

FAQ

Can I speak to someone?

Yes, email us at cruk@dsv.io

Does it matter where I’m based?

Remote is fine as long as you’re in a relevant cluster for your work (this includes outside the UK).

‘I have an idea…’

That’s great, the kind of people we’re looking for have lots of ideas, but you’ll need to be open to systematically breaking down a problem and not stuck on one idea, if that’s the case then we’d love to hear from you.

Are there labs?

We don’t have dedicated labs, as the kind of experiments we wish to do usually require specific kit and expertise. We do have a range of great relationships with existing labs and have supported many teams to work out a way forward with academic advisors or CROs for the initial proof of principle prior to seed investment.

What if it doesn’t work / I can’t find the solution?

We haven’t had a single case yet where we haven’t found a groundbreaking solution, but as a Founder if this happens you’ll likely join one of the labs you’ve been working with to prototype ideas, join a startup that you meet along the way, or work with one of the industry partners you’ve met. Overall, for a minor gap in blue-sky research you gain a world of connections and a wealth of impact experience that most labs are crying out for.

Who owns the IP?

The IP developed as part of the project will temporarily be held by DSV and assigned to the new company on formation. Any required background IP owned by research councils / charities / universities may be licensed via normal negotiation with those institutions. Where foreground IP is developed with a university, terms will be agreed as part of the research contact with that university.

Are there mentors?

Yes, both DSV and Cancer Research UK have a wide network of exited founders and investors. We think it’s pretty crass to have a big wall of faces, we’ll just connect you to the right people at the right time.

Interviews ongoing

Interviews ongoing